Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
The George Institute |
---|---|
Information provided by: | The George Institute |
ClinicalTrials.gov Identifier: | NCT00716079 |
The purpose of this academic lead study is to determine if a treatment strategy of early intensive blood pressure (BP) lowering compared to conservative BP lowering policy in patients with elevated blood pressure within 6 hours of acute intracerebral haemorrhage (ICH) improves the outcome of death and disability at 3 months after onset.
Condition | Intervention |
---|---|
Intracerebral Hemorrhage Stroke Hypertension Clinical Trial |
Other: Blood pressure management policies |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage. |
Estimated Enrollment: | 2800 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Intensive
Intensive Blood pressure (BP) lowering therapy is given via an intravenous drip for 24 hours. The target is to reach a systolic BP <140mmHg within 1 hour.
|
Other: Blood pressure management policies
The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
|
Conservative
Patients will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
|
Other: Blood pressure management policies
The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
|
Intracerebral haemorrhage (ICH) is one of the most serious subtypes of stroke, affecting over a million people worldwide each year, most of whom live in Asia. About one third of people with ICH die early after onset and the majority of survivors are left with major long-term disability. Despite the magnitude of the disease burden and cost on healthcare resources, there remains uncertainty about the role of surgery for ICH and no acute medical therapies have been shown to definitely alter outcome in ICH.
The INTERACT2 study follows the recently completed initial pilot study vanguard phase) which established the feasibility of the protocol, safety of early intensive BP lowering, and effects on haematoma expansion within 6 hours of onset of ICH. Having established 'proof-of-concept' that BP lowering may improve outcome by reducing haematoma expansion, INTERACT2 aims to establish the effects of the treatment on major clinical endpoints in patients with ICH recruited from an expanding clinical network around the world.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Emma Heeley, PhD | +61299934561 | eheeley@george.org.au |
Australia, New South Wales | |
Concord Hospital | |
Concord, New South Wales, Australia, 2138 | |
Gosford Hospital | |
Gosford, New South Wales, Australia, 2250 | |
John Hunter Hospital | |
Newcastle, New South Wales, Australia, 2310 | |
Royal Prince Alfred Hospital | |
Sydney, New South Wales, Australia, 2050 | |
St Vincent's Hospital | |
Sydney, New South Wales, Australia, 2010 | |
Westmead Hospital | |
Westmead, New South Wales, Australia, 2145 | |
Australia, Victoria | |
Alfred Hospital | |
Melbourne, Victoria, Australia, 3181 | |
Austin Health | |
Melbourne, Victoria, Australia | |
Box Hill Hospital | |
Melbourne, Victoria, Australia, 3128 | |
Monash Medical Centre | |
Melbourne, Victoria, Australia | |
Royal Melbourne Hospital | |
Melbourne, Victoria, Australia, 3050 | |
Australia, Western Australia | |
Sir Charles Gairdner Hospital | |
Perth, Western Australia, Australia, 6009 | |
China | |
Regional Coordinating Centre: Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Second Medical University | |
Shanghai, China, 200025 | |
Hospitals in China c/o The George Institute China | |
Beijing, China | |
France | |
Lariboisiere Hospital | |
Paris, France, 75475 |
Principal Investigator: | Craig Anderson, PhD | The George Institute |
Responsible Party: | The George Institute for International Health ( Porfessor Craig Anderson ) |
Study ID Numbers: | NHMRC-571281 |
Study First Received: | July 14, 2008 |
Last Updated: | July 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00716079 |
Health Authority: | Australia: National Health and Medical Research Council |
Cerebral Hemorrhage Stroke antihypertensive drugs blood pressure |
disability clinical trial outcomes |
Cerebral Hemorrhage Cerebral Infarction Hydralazine Clonidine Stroke Vascular Diseases Central Nervous System Diseases Intracranial Hemorrhages Hemorrhage Brain Diseases Metoprolol |
Cerebrovascular Disorders Urapidil Labetalol Phentolamine Enalapril Glycerol Esmolol Enalaprilat Metoprolol succinate Nicardipine Hypertension |
Vasodilator Agents Sympatholytics Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents |
Pharmacologic Actions Pathologic Processes Autonomic Agents Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Peripheral Nervous System Agents Anti-Arrhythmia Agents |